Sign inJoin waitlistJoin the waitlist

David Klonoff

Endocrinology, Diabetes & Metabolism · Ucsf Medical Group Business Services

Credentials: · ·

History

Endocrinology, Diabetes, and Metabolism
University of California (San Francisco) School of Medicine
1979–1981
Internal Medicine
UCLA Hospital
1976–1979
Univ of California, San Francisco Sch of Med
1972–1976
Genetics
1968–1972

Research

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
Current Medical Research and Opinion · 2008 · First of 8 authors · 549 citations
Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States
Journal of Diabetes Science and Technology · 2020 · Last of 7 authors · 487 citations
Threshold-based insulin-pump interruption for reduction of hypoglycemia
New England Journal of Medicine · 2013 · 459 citations

GU
Guillermo Umpierrez
32 papers · 25 as a fellow
JE
Juan Espinoza
22 papers
Trisha Shang
21 papers
Jane Seley
19 papers
NX
Nicole Xu
18 papers
RB
Richard Bergenstal
18 papers
Irl Hirsch
17 papers
Viral Shah
17 papers
Nestoras Mathioudakis
16 papers
DA
David Ahn
14 papers · 1 as a fellow
JS
Jennifer Sherr
14 papers
MK
Michael Kohn
14 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $51.6K · University of California, San Francisco
1998–1999

Clinical trials

Green Digital Diabetes Waste Project
Principal investigator · Completed
Florida State University
2023–2024
Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)
Principal investigator · Completed · Phase 2
Diasome Pharmaceuticals
2016–2018
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus
Principal investigator · Completed · Phase 3
Biodel
2006
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus
Principal investigator · Completed · Phase 3
Biodel
2006